Chapter 13

• The ester linkage is essential for effective binding of the anticholinergics to the acetylcholine receptors. This competitively blocks binding by acetylcholine and prevents receptor activation. The cellular effects of acetylcholine, which are mediated through second messengers, are inhibited.
• Anticholinergics relax the bronchial smooth musculature, which reduces airway resistance and increases anatomic dead space.
• Atropine has particularly potent effects on the heart and bronchial smooth muscle and is the most efficacious anticholinergic for treating bradyarrhythmias.
• Ipratropium solution (0.5 mg in 2.5 mL) seems to be particularly effective in the treatment of acute chronic obstructive pulmonary disease when combined with a β-agonist drug (eg, albuterol).
• Scopolamine is a more potent antisialagogue than atropine and causes greater central nervous system effects.
• Because of its quaternary structure, glycopyrrolate cannot cross the blood-brain barrier and is almost devoid of central nervous system and ophthalmic activity.

One group of cholinergic antagonists has already been discussed: the nondepolarizing neuromuscular-blocking agents. These drugs act primarily at the nicotinic receptors in skeletal muscle. This chapter presents the pharmacology of drugs that block muscarinic receptors. Although the classification anticholinergic usually refers to this latter group, a more precise term would be antimuscarinic.

In this chapter, the mechanism of action and clinical pharmacology are introduced for three common anticholinergics: atropine, scopolamine, and glycopyrrolate. The clinical uses of these drugs in anesthesia relate to their effect on the cardiovascular, respiratory, cerebral, gastrointestinal, and other organ systems (Table 13-1).

Table 13-1 Pharmacological Characteristics of Anticholinergic Drugs.1

### Mechanisms of Action

Anticholinergics are esters of an aromatic acid combined with an organic base (Figure 13-1). The ester linkage is essential for effective binding of the anticholinergics to the acetylcholine receptors. This competitively blocks binding by acetylcholine and prevents receptor activation. The cellular effects of acetylcholine, which are mediated through second messengers, are inhibited. The tissue receptors vary in their sensitivity to blockade. In fact, muscarinic receptors are not homogeneous, and receptor subgroups have been identified including: neuronal (M1), cardiac (M2), and glandular (M3) receptors.

###### Figure 13-1

Physical structures of anticholinergic drugs.

### Clinical Pharmacology

#### General Pharmacological Characteristics

In normal clinical doses, only muscarinic receptors are blocked by the anticholinergic drugs discussed in this chapter. The extent of the anticholinergic effect depends on the degree of baseline vagal tone. Several organ systems are affected.

##### Cardiovascular

Blockade of muscarinic receptors in the sinoatrial node ...

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.

Ok

## Subscription Options

### AccessAnesthesiology Full Site: One-Year Subscription

Connect to the full suite of AccessAnesthesiology content and resources including procedural videos, interactive self-assessment, real-life cases, 20+ textbooks, and more